Lipoproteins in chronic kidney disease: from bench to bedside DOI Open Access
Thimoteus Speer, Paul M. Ridker, Arnold von Eckardstein

et al.

European Heart Journal, Journal Year: 2020, Volume and Issue: 42(22), P. 2170 - 2185

Published: Dec. 9, 2020

Abstract Chronic kidney disease (CKD) is associated with high cardiovascular risk. CKD patients exhibit a specific lipoprotein pattern termed ‘uraemic dyslipidaemia’, which characterized by rather normal low-density cholesterol, low high-density and triglyceride plasma levels. All three classes are involved in the pathogenesis of CKD-associated diseases (CVDs). Uraemia leads to several modifications structure lipoproteins such as changes proteome lipidome, post-translational protein (e.g. carbamylation) accumulation small-molecular substances within moieties, affect their functionality. Lipoproteins from interfere lipid transport promote inflammation, oxidative stress, endothelial dysfunction well other features atherogenesis, thus contributing development CVD. While, lipid-modifying therapies play an important role management patients, efficacy modulated function. Novel therapeutic agents prevent adverse remodelling improve functional properties highly desirable partially under development.

Language: Английский

KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases DOI Creative Commons
Brad H. Rovin, Sharon G. Adler, Jonathan Barratt

et al.

Kidney International, Journal Year: 2021, Volume and Issue: 100(4), P. S1 - S276

Published: Sept. 20, 2021

The Kidney Disease: Improving Global Outcomes (KDIGO) 2021 Clinical Practice Guideline for the Management of Glomerular Diseases is an update to KDIGO 2012 guideline on topic. aim assist clinicians caring individuals with glomerular disease, both adults and children. scope includes various diseases, including IgA nephropathy (IgAN) vasculitis (IgAV), membranous nephropathy, nephrotic syndrome in children, minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), infection-related glomerulonephritis (GN), antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, lupus nephritis, anti-glomerular basement membrane (anti-GBM) GN. In addition, this will be first address subtype complement-mediated diseases. Each chapter follows same format providing guidance related diagnosis, prognosis, treatment, special situations. goal generate a useful resource patients by actionable recommendations valuable infographics based rigorous formal systematic literature review. Another propose research areas where there are gaps knowledge. targets broad audience treating while being mindful implications policy cost. Development followed explicit process evidence Treatment approaches reviews synthesis relevant studies, appraisal quality strength “Grading Recommendations Assessment, Development, Evaluation” (GRADE) approach. Limitations discussed, future also presented.

Language: Английский

Citations

1556
Podocytopathies DOI Open Access
Jeffrey B. Kopp, Hans‐Joachim Anders, Katalin Suszták

et al.

Nature Reviews Disease Primers, Journal Year: 2020, Volume and Issue: 6(1)

Published: Aug. 13, 2020

Language: Английский

Citations

362
Membranous nephropathy DOI Open Access
Pierre Ronco, Laurence H. Beck, Hanna Dêbiec

et al.

Nature Reviews Disease Primers, Journal Year: 2021, Volume and Issue: 7(1)

Published: Sept. 30, 2021

Language: Английский

Citations

290
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome DOI Creative Commons
Agnes Trautmann, Marina Vivarelli, Susan Samuel

et al.

Pediatric Nephrology, Journal Year: 2020, Volume and Issue: 35(8), P. 1529 - 1561

Published: May 7, 2020

Abstract Idiopathic nephrotic syndrome newly affects 1–3 per 100,000 children year. Approximately 85% of cases show complete remission proteinuria following glucocorticoid treatment. Patients who do not achieve within 4–6 weeks treatment have steroid-resistant (SRNS). In 10–30% patients, mutations in podocyte-associated genes can be detected, whereas an undefined circulating factor immune origin is assumed the remaining ones. Diagnosis and management SRNS a great challenge due to its heterogeneous etiology, frequent lack by further immunosuppressive treatment, severe complications including development end-stage kidney disease recurrence after renal transplantation. A team experts pediatric nephrologists geneticists from International Pediatric Nephrology Association (IPNA), pathologist, adult nephrologist now developed comprehensive clinical practice recommendations on diagnosis children. The performed systematic literature review 9 clinically relevant PICO ( P atient or opulation covered, I ntervention, C omparator, O utcome) questions, formulated formally graded them at consensus meeting, with input patient representatives dietician acting as external advisors voting panel nephrologists. Research are also given.

Language: Английский

Citations

271
Signaling pathways of chronic kidney diseases, implications for therapeutics DOI Creative Commons
Qian Yuan,

Ben Tang,

Chun Zhang

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2022, Volume and Issue: 7(1)

Published: June 9, 2022

Abstract Chronic kidney disease (CKD) is a chronic renal dysfunction syndrome that characterized by nephron loss, inflammation, myofibroblasts activation, and extracellular matrix (ECM) deposition. Lipotoxicity oxidative stress are the driving force for loss of including tubules, glomerulus, endothelium. NLRP3 inflammasome signaling, MAPK PI3K/Akt RAAS signaling involves in lipotoxicity. The upregulated Nox expression decreased Nrf2 result directly. injured resident cells release proinflammatory cytokines chemokines to recruit immune such as macrophages from bone marrow. NF-κB JAK-STAT Toll-like receptor cGAS-STING major pathways mediate inflammation inflammatory cells. produce secret great number profibrotic TGF-β1, Wnt ligands, angiotensin II. TGF-β Notch evoke activation promote generation ECM. potential therapies targeted these also introduced here. In this review, we update key lipotoxicity, stress, kidneys with injury, drugs based on latest studies. Unifying will be instrumental advance further basic clinical investigation CKD.

Language: Английский

Citations

225
Lipid management in patients with chronic kidney disease DOI
Charles J. Ferro, Patrick B. Mark, Mehmet Kanbay

et al.

Nature Reviews Nephrology, Journal Year: 2018, Volume and Issue: 14(12), P. 727 - 749

Published: Oct. 25, 2018

Language: Английский

Citations

210
Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022 DOI Open Access
Tomonori Okamura, Kazuhisa Tsukamoto, Hidenori Arai

et al.

Journal of Atherosclerosis and Thrombosis, Journal Year: 2023, Volume and Issue: 31(6), P. 641 - 853

Published: Dec. 18, 2023

Language: Английский

Citations

141
The key role of altered tubule cell lipid metabolism in kidney disease development DOI Creative Commons
Lauren E. Lee, Tomohito Doke, Dhanunjay Mukhi

et al.

Kidney International, Journal Year: 2024, Volume and Issue: 106(1), P. 24 - 34

Published: April 16, 2024

Kidney epithelial cells have very high energy requirements, which are largely met by fatty acid oxidation. Complex changes in lipid metabolism observed patients with kidney disease. Defects oxidation and increased uptake, especially the context of hyperlipidemia proteinuria, contribute to this excess build-up exacerbate disease development. Recent studies also highlighted role de novo lipogenesis fibrosis. The defect causes starvation. Increased synthesis, lower can cause toxic build-up, reactive oxygen species generation, mitochondrial damage. A better understanding these metabolic processes may open new treatment avenues for diseases targeting metabolism.

Language: Английский

Citations

24
Disorders of Lipid Metabolism in Chronic Kidney Disease DOI Open Access

Mustafa C. Bulbul,

Tuncay Dağel, Barış Afşar

et al.

Blood Purification, Journal Year: 2018, Volume and Issue: 46(2), P. 144 - 152

Published: Jan. 1, 2018

Cardiovascular disease (CVD) is the leading cause of death in chronic kidney (CKD). One most important pathophysiological mechanisms for CVD patients with CKD widespread and possibly accelerated formation atherosclerotic plaques due to hyperlipidemia, uremic toxins, inflammation, oxidative stress, endothelial dysfunction. Recent studies showed that level oxidized low-density lipoprotein cholesterol increases, high--density dysfunction occurs as function declines inflammation becomes more prevalent. In this review, we aimed discuss effect dysfunction, on lipid -profile.

Language: Английский

Citations

128
Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease DOI Open Access
Asier Benito‐Vicente, Kepa B. Uribe,

Shifa Jebari

et al.

International Journal of Molecular Sciences, Journal Year: 2018, Volume and Issue: 19(11), P. 3426 - 3426

Published: Nov. 1, 2018

Cholesterol is an essential component of cell barrier formation and signaling transduction involved in many physiologic processes. For this reason, cholesterol metabolism must be tightly controlled. Cell mainly acquired from two sources: Dietary cholesterol, which absorbed the intestine and, intracellularly synthesized that liver. Once acquired, both are delivered to peripheral tissues a lipoprotein dependent mechanism. Malfunctioning caused by multiple hereditary diseases, including Familial Hypercholesterolemia, Sitosterolemia Type C Niemann-Pick C1. Of these, familial hypercholesterolemia (FH) common inherited autosomal co-dominant disorder characterized high plasma levels. Its frequency estimated 1:200 if untreated, increases risk premature cardiovascular disease. This review aims summarize current knowledge on relation FH homeostasis with special focus genetics, diagnosis treatment.

Language: Английский

Citations

113